Compare Stocks: GRAL, BMRN, MDGL, and HALO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.45 -3.0%	$63.53	$49.26 ▼ $70.98	$12.86B	0.24	1.68 million shs	1.85 million shs
GRAL GRAIL	$75.89 +0.5%	$73.77	$36.98 ▼ $118.84	$3.37B	3.25	617,014 shs	1.51 million shs
HALO Halozyme Therapeutics	$106.25 -1.6%	$94.77	$61.22 ▼ $111.15	$12.25B	0.88	1.46 million shs	1.06 million shs
MDGL Madrigal Pharmaceuticals	$523.26 -3.1%	$530.76	$393.61 ▼ $615.00	$12.48B	-0.98	203,343 shs	259,410 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-2.95%	-0.28%	-4.32%	+17.14%	+21.28%
GRAL GRAIL	+0.48%	-4.06%	+11.82%	+27.65%	+92.96%
HALO Halozyme Therapeutics	-1.57%	-1.90%	+7.69%	+54.95%	+39.20%
MDGL Madrigal Pharmaceuticals	-3.11%	-2.04%	+3.09%	+4.68%	+22.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.45 -3.0%	$63.53	$49.26 ▼ $70.98	$12.86B	0.24	1.68 million shs	1.85 million shs
GRAL GRAIL	$75.89 +0.5%	$73.77	$36.98 ▼ $118.84	$3.37B	3.25	617,014 shs	1.51 million shs
HALO Halozyme Therapeutics	$106.25 -1.6%	$94.77	$61.22 ▼ $111.15	$12.25B	0.88	1.46 million shs	1.06 million shs
MDGL Madrigal Pharmaceuticals	$523.26 -3.1%	$530.76	$393.61 ▼ $615.00	$12.48B	-0.98	203,343 shs	259,410 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-2.95%	-0.28%	-4.32%	+17.14%	+21.28%
GRAL GRAIL	+0.48%	-4.06%	+11.82%	+27.65%	+92.96%
HALO Halozyme Therapeutics	-1.57%	-1.90%	+7.69%	+54.95%	+39.20%
MDGL Madrigal Pharmaceuticals	-3.11%	-2.04%	+3.09%	+4.68%	+22.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.74	Moderate Buy	$89.17	38.36% Upside
GRAL GRAIL	2.36	Hold	$71.11	-6.30% Downside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-14.16% Downside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$699.64	33.71% Upside

Current Analyst Ratings Breakdown

Latest GRAL, BMRN, MDGL, and HALO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$60.00
9/9/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$105.00
9/9/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$105.00
9/3/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/2/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
9/1/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$88.00 ➝ $90.00
8/31/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/31/2026	BMRN BioMarin Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$104.00 ➝ $105.00
8/31/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$59.00 ➝ $60.00
8/26/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$88.00
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.87	$2.77 per share	23.27	$31.68 per share	2.03
GRAL GRAIL	$147.17M	23.03	N/A	N/A	$66.13 per share	1.15
HALO Halozyme Therapeutics	$1.66B	7.25	$4.70 per share	22.62	$0.42 per share	252.98
MDGL Madrigal Pharmaceuticals	$958.40M	12.61	N/A	N/A	$26.54 per share	19.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	174.19	11.83	0.48	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
GRAL GRAIL	-$408.35M	-$9.75	N/A	N/A	N/A	-236.95%	-15.88%	-14.02%	11/11/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	31.72	11.39	0.41	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	94.28	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)

Latest GRAL, BMRN, MDGL, and HALO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/5/2026	Q2 2026	GRAL GRAIL	-$2.66	-$2.56	+$0.10	-$2.56	$42.39 million	$44.69 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
GRAL GRAIL	N/A	10.95	10.95
HALO Halozyme Therapeutics	13.50	2.71	2.31
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
GRAL GRAIL	N/A
HALO Halozyme Therapeutics	97.79%
MDGL Madrigal Pharmaceuticals	98.50%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
GRAL GRAIL	1.83%
HALO Halozyme Therapeutics	2.50%
MDGL Madrigal Pharmaceuticals	17.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
GRAL GRAIL	910	44.67 million	43.85 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable
MDGL Madrigal Pharmaceuticals	915	23.10 million	19.04 million	Optionable

GRAL, BMRN, MDGL, and HALO Headlines

Recent News About These Companies

Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO Sells 5,221 Shares of Stock

September 12, 2026 | insidertrades.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO William John Sibold Sells 5,221 Shares

September 11, 2026 | marketbeat.com

William John Sibold Sells 6,362 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

September 11, 2026 | marketbeat.com

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 10, 2026 | seekingalpha.com

Hsbc Holdings PLC Grows Stake in Madrigal Pharmaceuticals, Inc. $MDGL

September 10, 2026 | marketbeat.com

Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by California State Teachers Retirement System

September 10, 2026 | marketbeat.com

Public Employees Retirement System of Ohio Invests $2.74 Million in Madrigal Pharmaceuticals, Inc. $MDGL

September 6, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL

September 5, 2026 | marketbeat.com

Legal & General Group Plc Invests $6.63 Million in Madrigal Pharmaceuticals, Inc. $MDGL

September 3, 2026 | marketbeat.com

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference

September 2, 2026 | markets.businessinsider.com

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference

September 2, 2026 | globenewswire.com

Two Sigma Securities LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL

September 1, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Invests $6.55 Million in Madrigal Pharmaceuticals, Inc. $MDGL

August 31, 2026 | marketbeat.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of "Moderate Buy" by Analysts

August 31, 2026 | marketbeat.com

Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Wellington Management Group LLP

August 30, 2026 | marketbeat.com

Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Algert Global LLC

August 30, 2026 | marketbeat.com

Hsbc Holdings PLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL

August 29, 2026 | marketbeat.com

Canada Pension Plan Investment Board Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL

August 29, 2026 | marketbeat.com

Bamco Inc. NY Makes New $2.42 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Makes New $2.67 Billion Investment in Madrigal Pharmaceuticals, Inc. $MDGL

August 27, 2026 | marketbeat.com

Castleark Management LLC Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL, BMRN, MDGL, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$64.45 -1.96 (-2.95%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$64.65 +0.20 (+0.31%)

As of 07:24 AM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

GRAIL NASDAQ:GRAL

$75.89 +0.36 (+0.48%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$75.99 +0.10 (+0.13%)

As of 07:01 AM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Halozyme Therapeutics NASDAQ:HALO

$106.25 -1.69 (-1.57%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$106.75 +0.50 (+0.47%)

As of 08:00 AM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$523.26 -16.80 (-3.11%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$523.73 +0.47 (+0.09%)

As of 09/15/2026 07:30 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRAL, BMRN, MDGL, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRAL, BMRN, MDGL, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRAL, BMRN, MDGL, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL, BMRN, MDGL, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

GRAIL NASDAQ:GRAL

Halozyme Therapeutics NASDAQ:HALO

Madrigal Pharmaceuticals NASDAQ:MDGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRAL, BMRN, MDGL, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRAL, BMRN, MDGL, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRAL, BMRN, MDGL, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL, BMRN, MDGL, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

GRAIL NASDAQ:GRAL

Halozyme Therapeutics NASDAQ:HALO

Madrigal Pharmaceuticals NASDAQ:MDGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools